This web site uses cookies. Do you accept the use of external cookies? Yes No Know more x
Survey about achondroplasia
We have designed a questionnaire with the purpose to better know the population connected to achondroplasia.
The questionnaire is optional and anonymous. The data obtained will be used for statistical purposes and to better understand the natural history of achondroplasia. Please consider answering.
If you would like to take the survey later, you can click on the link at the top "Register at BA"
Go to the survey Not now No, thanks

[Free Full Text] Final adult height in long-term growth hormone-treated achondroplasia patients

  • Home•
  • Library•
  • Therapies•
  • [Free Full Text] Final adult height in long-term growth hormone-treated achondroplasia patients

There are several therapies that increase height in achondroplasia patients. Among these, growth hormone (GH) administration has been a controversial subject for not contributing significantly to final height in patients who underwent this treatment.

Below, a paper published in 2017 has found that GH treatment resulted in an increase in height of 2.6% in males and 2.1% in females in the japanese achondroplastic population , although the study had some limitations, such as a small sample size:

Harada, D., et al., Final adult height in long-term growth hormone-treated achondroplasia patients. European Journal of Pediatrics, 2017: p. 1-7.
Available here. 

Abstract:

"The objective of this study was to evaluate the gain in final height of achondroplasia (ACH) patients with long-term growth hormone (GH) treatment. We analyzed medical data of 22 adult patients (8 males and 14 females) treated with GH at a dose of 0.05 mg/kg/day. Optionally, tibial lengthening (TL) was performed with the Ilizalov method in 15 patients and TL as well as femoral lengthening (FL) in 6 patients. Concomitant gonadal suppression therapy with buserelin acetate was applied in 13 patients. The mean treatment periods with GH were 10.7 ± 4.0 and 9.3 ± 2.5 years for males and females, respectively. GH treatment augmented the final height +0.60 ± 0.52 SD (+3.5 cm) and +0.51 ± 1.29 SD (+2.8 cm) in males and females compared to non-treated ACH patients, respectively. Final height of ACH patients that underwent GH and TL increased +1.72 ± 0.72 SD (+10.0 cm) and +1.95 ± 1.34 SD (+9.8 cm) in males and females, respectively. GH, TL, and FL increased their final height +2.97 SD (+17.2 cm) and +3.41 ± 1.63 SD (+17.3 cm) in males and females, respectively. Gonadal suppression therapy had no impact on final height.
Conclusions: Long-term GH treatment contributes to 2.6 and 2.1% of final adult height in male and female ACH patients, respectively."
To view this site you need Internet Explorer 8 (or a higher version)
or another internet browser.

Thank You.